Response to first-line chemotherapy (DC vs. no DC), KRAS mutational status (mutated vs. wild-type), T2D (present vs. not present), BMI (>25 kg/m2 vs. normal), and concomitant presence of T2D, BMI, and HT associated with survival at univariate analysis (Table 4). This evidence concerns the gene KRAS and type 2 diabetes mellitus.